1. Home
  2. SEAT vs AUTL Comparison

SEAT vs AUTL Comparison

Compare SEAT & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vivid Seats Inc.

SEAT

Vivid Seats Inc.

HOLD

Current Price

$7.83

Market Cap

79.0M

Sector

Industrials

ML Signal

HOLD

Logo Autolus Therapeutics plc

AUTL

Autolus Therapeutics plc

HOLD

Current Price

$1.99

Market Cap

532.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SEAT
AUTL
Founded
2001
2014
Country
United States
United Kingdom
Employees
565
752
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
79.0M
532.3M
IPO Year
N/A
2025

Fundamental Metrics

Financial Performance
Metric
SEAT
AUTL
Price
$7.83
$1.99
Analyst Decision
Buy
Strong Buy
Analyst Count
8
4
Target Price
$18.06
$8.50
AVG Volume (30 Days)
68.9K
1.9M
Earning Date
05-05-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$10,120,000.00
Revenue This Year
N/A
$80.32
Revenue Next Year
$4.60
$53.96
P/E Ratio
N/A
N/A
Revenue Growth
N/A
496.00
52 Week Low
$5.06
$1.18
52 Week High
$18.73
$2.52

Technical Indicators

Market Signals
Indicator
SEAT
AUTL
Relative Strength Index (RSI) 52.17 70.85
Support Level $7.29 $1.31
Resistance Level $8.68 $2.07
Average True Range (ATR) 0.71 0.13
MACD 0.12 0.06
Stochastic Oscillator 48.65 88.57

Price Performance

Historical Comparison
SEAT
AUTL

About SEAT Vivid Seats Inc.

Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry, providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada, and Japan. It operates in two segments: Marketplace, which generates maximum revenue, and Resale. The Marketplace segment acts as an intermediary between ticket buyers, sellers, and partners, earning revenue from processing ticket sales for live events and facilitating the booking of hotel rooms and packages on websites and mobile applications. The Resale segment acquires tickets to resell on secondary ticket marketplaces, including its own, and offers internal research and development support for Skybox.

About AUTL Autolus Therapeutics plc

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.

Share on Social Networks: